GJA1 and proximal spinal muscular atrophy: Future work should therefore employ conditional, astrocyte-specific Cx43 knockout models and evaluate clinically tested gap junction modulators such as Tonabersat [40,41,42] in different phenotype-related SMA models to determine their therapeutic potential.